Format

Send to

Choose Destination
IDrugs. 2006 May;9(5):354-60.

Drug evaluation: ProCord - a potential cell-based therapy for spinal cord injury.

Author information

1
Department of Molecular Virology, Immunology & Medical Genetics, Department of Neuroscience, Ohio State University College of Medicine, 2078 Graves Hall, 333 West 10th Avenue, Columbus, OH 43210, USA.

Abstract

Proneuron Biotechnologies Inc is developing ProCord, an activated macrophage cell therapy, for the potential treatment of neurological conditions. In September 2004, ProCord was granted Orphan Drug status by the US Food and Drug Administration for the treatment of acute spinal cord injury.

PMID:
16676272
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center